Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

A self-deactivating cytokine platform technology

Objetivo

Adoptive cell therapies harness the power of our immune system to treat and even cure severe diseases from cancer via infections to autoimmunity. These emerging therapies use engineered lymphocytes to fight disease-causing cells in patients and major progress has been achieved in the treatment of blood cancers. In contrast, solid tumors remain notoriously difficult to treat with adoptive cell therapies. Very often, this is due to the strongly immunosuppressive microenvironment of solid cancers, limiting the effectiveness of cell therapies.

Cytokines with their potent immunoregulatory functions can alleviate these challenges. A paradigm for this is interleukin 12 (IL-12). IL-12 has strong immune-activating properties, increases antigen presentation, and inhibits or reprograms otherwise immunosuppressive cells in the tumor microenvironment. Despite this ideal signature, IL-12 has fallen short of its promises in the clinics – mainly due to dose-limiting toxicity. Maintaining a maximum IL-12 concentration at desired sites of action while concurrently keeping the systemic level low is thus a major dilemma when it comes to using IL-12 in the clinics.

We have developed a self-deactivating IL-12 that is only active at the site of production and release, e.g. from CAR T cells. As such, it makes the desired properties of IL-12 available at relevant sites while avoiding systemic effects. Building on strong preliminary data and a team with complementary expertise, this project will i) provide in vivo Proof of Concept data ii) secure the IP for the locally active IL-12 and iii) take major steps towards commercialization of the technology.

Our platform technology will make adoptive cell therapies for solid tumors more effective while maintaining their safety. Further applications lie in virus- and nucleic acid-based therapeutic approaches thus making this technology highly attractive to companies developing different modalities in the space of next generation immunotherapy.

Ámbito científico (EuroSciVoc)

Este proyecto aún no se ha clasificado con EuroSciVoc.
Sugiera los ámbitos científicos que considere más relevantes y ayúdenos a mejorar nuestro servicio de clasificación.

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2026-POC

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

TECHNISCHE UNIVERSITAET MUENCHEN
Aportación neta de la UEn
€ 150 000,00
Dirección
Arcisstrasse 21
80333 Muenchen
Alemania
Región
Bayern Oberbayern München, Kreisfreie Stadt
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Beneficiarios (1)